Condition
Brain Glioma
Total Trials
5
Recruiting
1
Active
1
Completed
2
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
Termination Rate
0.0%
0 terminated out of 5 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
20%
1 trials in Phase 3/4
Results Transparency
0%
0 of 2 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
3Total
Not Applicable (2)
P 3 (1)
Trial Status
Unknown2
Completed2
Recruiting1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (5)
Showing 5 of 5 trials
NCT03984240Not ApplicableCompletedPrimary
The Effects of Mild Sedation on Motor Function Networks in Patients With Brian Gliomas
NCT06747728Not ApplicableRecruitingPrimary
Bevacizumab Neoadjuvant Therapy for New High-grade Gliomas in the Brain
NCT05595863UnknownPrimary
Correlation Between SPECT/CT and IDH Mutation in Brain Glioma
NCT05593809UnknownPrimary
Single Photon Emission Computed Tomography/Computed Tomography With Pentavalent 99mTc Dimercaptosuccinic Acid in Patients With Brain Glioma; Correlation With IDH Mutation
NCT03042416Phase 3Completed
18F-DOPA PET Imaging: an Evaluation of Biodistribution and Safety
Showing all 5 trials